4′-Thio-Modified mRNA for Stable In Vivo Therapeutic Protein Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The poor stability of messenger RNA (mRNA) in vivo due to degradation by nucleases limits the efficacy of gene therapy for protein production, as the mRNA is not translated effectively, leading to insufficient therapeutic protein production.
Innovation Solution
Incorporation of 4′-thio-modified nucleotides in the ribose moiety of mRNA to enhance stability and resistance to nuclease degradation, allowing for sustained in vivo protein production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If unmodified mRNA is administered for gene therapy, then the treatment approach is simple and direct, but the mRNA stability is poor due to degradation by nucleases
Solution Approach 1:
The patent applies parameter changes by substituting the 4' oxygen atom in the ribose moiety with a sulfur atom to create 4'-thio-modified nucleotides. This chemical parameter change fundamentally alters the mRNA's resistance to nuclease degradation, directly resolving the contradiction between maintaining simplicity and improving stability. The sulfur substitution is a specific parameter modification that enhances reliability without requiring complex delivery systems or packaging.
Solution Approach 2:
The patent creates a composite nucleic acid structure by incorporating 4'-thio-modified nucleotides into the mRNA sequence. This composite approach combines modified and unmodified nucleotides (or fully modified sequences) to produce an mRNA molecule with enhanced stability properties. The composite nature of the modified mRNA allows it to resist nuclease degradation while maintaining translational functionality, resolving the stability-simplicity contradiction.
2Reliability
If mRNA is packaged with polymer or lipid carrier to improve stability, then the mRNA stability increases, but the administration complexity and cost increase
Solution Approach 1:
The patent extracts the stability-enhancing function from the mRNA molecule itself by incorporating 4'-thio-modified nucleotides directly into the sequence. This eliminates the need for external packaging carriers (polymers or lipids) that would otherwise be required to protect unmodified mRNA. By taking out the protection function and embedding it within the mRNA structure through chemical modification, the patent simplifies the administration process while maintaining stability.
Solution Approach 2:
The modified mRNA performs self-protection against nuclease degradation through its inherent 4'-thio modification. Instead of requiring external carriers or packaging for protection, the mRNA molecule itself possesses the stability-enhancing property. This self-service approach eliminates complex manufacturing and administration steps associated with carrier-based delivery systems.
3Productivity
If high levels of nuclease degradation occur, then the mRNA circulatory half-life is shortened, but this leads to insufficient therapeutic protein production
Solution Approach 1:
The patent applies beforehand cushioning by pre-modifying the mRNA with 4'-thio nucleotides before administration to protect it against upcoming nuclease degradation in the circulatory system. This prior protection ensures that the mRNA maintains its integrity and circulatory half-life is extended, allowing sufficient time for therapeutic protein production. The modification acts as a preemptive measure against the harmful degradation that would otherwise limit productivity.
Solution Approach 2:
The 4'-thio modification provides preliminary anti-action by preemptively blocking nuclease attack sites on the mRNA molecule. This preliminary protective action prevents the harmful degradation that would otherwise shorten circulatory half-life and reduce therapeutic protein production. The sulfur substitution creates steric and chemical barriers that counteract nuclease activity before degradation can occur.
Data Source
AI summary
Disclosed are messenger RNA molecules and related compositions incorporating a 4′-thio modification in the furanose ring of at least one nucleotide residue, and methods of using these mRNAs to produce an encoded therapeutic protein in vivo and to treat or prevent diseases or disorders. In certain embodiments, the 4′-thio modified mRNA provides for enhanced stability and/or reduced immunogenicity in in vivo therapies.